The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 21, 2020
Filed:
Apr. 22, 2016
Applicant:
Relmada Therapeutics, Inc., New York, NY (US);
Inventor:
Najib Babul, Blue Bell, PA (US);
Assignee:
Relmada Therapeutics, Inc., New York, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/485 (2006.01); A61K 9/50 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 9/48 (2006.01);
U.S. Cl.
CPC ...
A61K 31/485 (2013.01); A61K 9/006 (2013.01); A61K 9/0053 (2013.01); A61K 9/1635 (2013.01); A61K 9/1676 (2013.01); A61K 9/2054 (2013.01); A61K 9/2866 (2013.01); A61K 9/4858 (2013.01); A61K 9/4891 (2013.01); A61K 9/50 (2013.01);
Abstract
The present invention is directed to oral, therapeutically effective modified release pharmaceutical compositions of (−)-17-(cyclobutylmethyl)morphinan-3,14-diol and it pharmaceutically acceptable salts and the use thereof, including delayed onset and extended release dosage forms. The present invention is also directed at modified release dosage forms of oral (−)-17-(cyclobutylmethyl)morphinan-3,14-dial which provide robust efficacy and reduced potential for abuse and misuse.